Rituksimab

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Rituksimab
Klinički podaci
Robne marke MabThera, Rituxan
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 174722-31-7
ATC kod L01XC02
DrugBank DB00073
ChEMBL[1] CHEMBL1201576 YesY
Hemijski podaci
Formula C6416H9874N1688O1987S44 
Mol. masa 143859.7 g/mol
Fizički podaci
Tačka topljenja 61 °C (142 °F)
Farmakokinetički podaci
Poluvreme eliminacije 0,8 h
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Intravenozno

Rituksimab (Rituxan, MabThera) je himerno monoklonalno antitelo protiv proteina CD20, koji je prvenstveno prisutan na površini imunskih B ćelija. Rituksimab uništava B ćelije i stoga se koristi za lečenje bolesti koji su karakterisane prekomernim brojem B ćelija, preaktivnim B ćelijama, ili disfunkcionim B ćelijama. Time su obuhvaćeni mnogi limfomi, leukemije, odbacivanja transplantata, i autoimunske bolesti.[2][3][4][5][6][7][8][9]

Reference[uredi - уреди | uredi izvor]

  1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  2. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. PMID 9704735
  3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N En
  4. gl J Med. 2004 Jun 17;350(25):2572-81. PMID 15201414
  5. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005 Apr;78(4):275-80. PMID 15795920
  6. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M: The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8. Epub 2006 May 16. PMID 16705086
  7. Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003 Jun 26;348(26):2690-1; discussion 2690-1. PMID 12826649
  8. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. PMC 3013709. PMID 21059682. doi:10.1093/nar/gkq1126.  edit
  9. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic acids research 36 (Database issue): D901–6. PMC 2238889. PMID 18048412. doi:10.1093/nar/gkm958.  edit

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).